Gosset Ownership
Private
Employees
~15
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
PanOptica General Information
PanOptica’s lead compound, PAN-90806, is a novel small-molecule selective VEGF receptor antagonist being developed as a topical eye drop for the treatment of neovascular age-related macular degeneration and other sight-threatening eye diseases. Clinical development has reached Phase 2 for wet AMD. The company is also developing additional assets such as PAN-90716-DES for broader eye disease indications[1][4].
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Mount Arlington, New Jersey
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
No major pharmaceutical partnerships publicly disclosed; investors include SV Life Sciences and Novo A/S
PanOptica Funding
No funding data available
To view PanOptica's complete valuation and funding history, request access »